<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440410</url>
  </required_header>
  <id_info>
    <org_study_id>YDC-2</org_study_id>
    <nct_id>NCT04440410</nct_id>
  </id_info>
  <brief_title>Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis</brief_title>
  <official_title>Non-interventional Study to Evaluate Cutaneous and Circulating Inflammatory Biomarkers for a Novel IRAK4-targeted Therapeutic in Hidradenitis Suppurativa and Atopic Dermatitis Patient Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kymera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>York Dermatology Clinic and Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kymera Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-intervention study will identify the biomarker profiles in hidradenitis suppurativa
      (HS) and atopic dermatitis (AD) (as a comparator) that would have the most utility in
      interventional studies evaluating efficacy during therapeutic intervention. Study data will
      also be used to correlate cellular/molecular changes in blood (cells and serum), and tissue,
      with clinical/histopathological phenotypes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an exploratory correlative study in subjects with HS or AD. Blood samples and
      skin biopsies will be collected from all subjects and used to assess the following: cutaneous
      and circulating inflammatory biomarkers and IRAK4 target levels in primary samples,
      correlations between cutaneous and circulating inflammatory biomarkers and disease severity,
      effects of IRAK4 degradation on IRAK4 levels and downstream inflammatory biomarkers in ex
      vivo-treated whole blood from patients.

      De-identified routine clinical data that is collected will be correlated with the research
      findings.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker Identification</measure>
    <time_frame>Day 1</time_frame>
    <description>Assessment of cutaneous and circulating inflammatory biomarkers and IRAK4 target levels in primary samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of Biomarker Correlations</measure>
    <time_frame>Day 1</time_frame>
    <description>Determine correlations between cutaneous and circulating inflammatory biomarkers and disease severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examination of IRAK4 Degradation Effects Ex Vivo</measure>
    <time_frame>Day 1</time_frame>
    <description>Examine effect of IRAK4 degrader on IRAK4 levels and downstream inflammatory biomarkers in ex vivo-treated whole blood from patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Hidradenitis suppurativa</arm_group_label>
    <description>Subjects with active mild, moderate, or severe HS disease using the HS-PGA assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic Dermatitis</arm_group_label>
    <description>Subjects with active moderate or severe AD disease using the PGA assessment</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples, skin biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with active mild, moderate, or severe HS or active moderate or severe AD disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or older

          2. Active HS or AD disease, diagnosed by PI

          3. Patients with mild (HS only), moderate, or severe disease using the HS-PGA or PGA
             assessment.

          4. Must sign an informed consent form (ICF) indicating that he or she understands the
             purpose of and procedures required for the study, and is willing to participate in the
             study.

        Exclusion Criteria:

          1. Patient is currently on a biologic or other immunosuppressive treatment for HS or AD.

          2. Use of biologic treatment for HS or AD within 3 months or 5 half-lives, whichever is
             longer

          3. Use of non-biologic immunosuppressive treatment (eg. Cyclosporin) in the last 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afsaneh Alavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>York Dermatology Clinic and Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alice McDonald</last_name>
    <phone>857-285-5300</phone>
    <phone_ext>821</phone_ext>
    <email>alice@kymeratx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>York Dermatology Clinic and Research Centre</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afsaneh Alavi, MD</last_name>
      <phone>905-883-4472</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IRAK4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

